The data showing a range of concentrations in the CNS metastases rings true intended for the clinical experience in which the occasional patient has a noticeable response in the brain to systemic chemotherapy

The data showing a range of concentrations in the CNS metastases rings true intended for the clinical experience in which the occasional patient has a noticeable response in the brain to systemic chemotherapy. cancer in 1998; an improved time to progression from 4. SAT1 5 to 7. 2 months was noticed with the antibody in combination with chemotherapy [2]. With longer response durations, a disturbing trend emerged: Butylphthalide a high incidence of CNS metastases in patients whose systemic disease was in remission or under control [3]. Biologically speaking, this should not have been surprising, given that most anticancer drugs, and particularly large molecules such as antibodies, cross the blood-brain barrier (BBB) very poorly. The cornerstone of treatment intended for CNS metastatic disease is whole-brain radiotherapy (WBRT), often with stereotactic radiosurgery (SRS) to specific lesions; however , intracranial recurrence is frequent after WBRT or SRS, and the combination of the two does not increase survival [46]. Consequently, other active therapies are needed. As systemic therapies improve, this problem of our success has become an increasing problem past HER2-positive breast cancer, as for example with EGFR or ALK-mutated lung cancer. == The BloodBrain Barrier in CNS Metastasis Is Real == Whether metastatic lesions are protected by a BBB has been a subject of controversy. There is agreement that in the regular brain, the BBB, with its drug transporters and tight junctions, prevents entry of many drugs [7]. Molecular size, low lipophilicity, and susceptibility to the mulitdrug transporter are among the important factors that limit CNS accumulation of Butylphthalide most drugs. The vascular endothelium generated in association with metastasis appears to be less restrictive than the actual endothelium from the normal BBB but more so than in peripheral metastases. In a carefully analyzed animal model of MDA-MB-231 breast cancer cells selected for their propensity to metastasize to the CNS, paclitaxel levels in regular brain ranged from 10 to 80 ng/g and in CNS metastases from 100 to 1000 ng/g, both ideals far lower than the 10, 000- to 100, 000-ng/g range found in systemic metastases [8]. The data showing a range of concentrations in the CNS metastases rings true intended for the clinical experience in which the occasional patient has a noticeable response in the brain to systemic chemotherapy. Additional evidence in patients came in a recent report in which capecitabine and lapatinib were measured in surgical resection samples, with high variability (range: 0. 199. 8) noted intended for lapatinib when compared with serum levels [9]. Although more data are needed in patients, these and other studies argue strongly for the presence of a partially intact BBB Butylphthalide in metastatic disease. == CNS Metastases Often Do Not Require Immediate Radiotherapy == With time, we have achieved greater understanding of the problem and with it some paradigm shifts. Two decades ago the observation of even a single CNS metastatic first deposit called for corticosteroids and antiseizure medication , and an immediate referral for radiotherapy. We now know that the immediate danger Butylphthalide from untreated, asymptomatic, or mildly symptomatic CNS metastasis is quite low and that there is a window of opportunity in which experimental therapy can and should be attempted. The SCENERY trial screening lapatinib and capecitabine in otherwise untreated brain metastases from HER2+ breast cancer reported a partial response rate of 65. 9% responses [10]. These results were greeted with widespread enthusiasm and represent exactly the type of study that is needed. Enthusiasm is somewhat tempered by Butylphthalide the rather brief 5. 5-month median CNS progression-free survival (PFS) in these patients without prior WBRT. While the trial offers hope for patients with HER2+ tumors, it offers no help to the other subclasses of breast cancer, but does indicate the potential for systemic drug treatment intended for CNS metastases. It is worth noting that new inhibitors of EML4-ALK, such as ceritinib, produce responses in CNS disease, offering further proof that better drugs.